Understand the source comparison
Best Research Peptides for Visceral Fat Reduction: Research Comparison
The following table compares the primary research peptides studied for visceral adipose tissue reduction across mechanism, administration, and documented outcomes. CJC-1295 (with DAC) GHRH receptor agonist; stimulates endogenous GH pulses 6–8 days 1–2mg subcut
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table compares the primary research peptides studied for visceral adipose tissue reduction across mechanism, administration, and documented outcomes.
- CJC-1295 (with DAC)
- GHRH receptor agonist; stimulates endogenous GH pulses
- 6–8 days
- 1–2mg subcutaneous, twice weekly
- 15–22% reduction in rodent visceral fat pads over 12 weeks
- Sustained GH elevation with minimal dosing frequency. Excellent for multi-week protocols
- Tesamorelin
- Synthetic GHRH analogue; pituitary GH release
- 26–38 minutes
- 2mg subcutaneous, daily
- 15.2–18.1% VAT reduction in human trials (26 weeks)
- Gold standard in human visceral fat research. FDA-reviewed safety profile
- AOD-9604
- hGH fragment 176-191; beta-3 receptor agonist
- 1.5–2 hours
- 250–500 mcg subcutaneous, daily
- 2.6kg greater fat loss vs placebo (12 weeks, human Phase IIa)
- Lipolytic effect without glucose or IGF-1 disruption. Safer metabolic profile than full GH
- MOTS-c
- Mitochondrial-derived peptide; AMPK activation, nuclear gene regulation
- ~2 hours
- 5–15mg subcutaneous, 2–3x weekly
- 27% visceral fat pad reduction in diet-induced obesity models
- Unique mitochondrial pathway. Addresses insulin resistance and fat oxidation simultaneously